Lyka Labs Limited (LYKALABS) - Net Assets

Latest as of September 2025: Rs1.01 Billion INR ≈ $10.96 Million USD

Based on the latest financial reports, Lyka Labs Limited (LYKALABS) has net assets worth Rs1.01 Billion INR (≈ $10.96 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs1.68 Billion ≈ $18.15 Million USD) and total liabilities (Rs664.32 Million ≈ $7.18 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Lyka Labs Limited to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs1.01 Billion
% of Total Assets	60.41%
Annual Growth Rate	6.64%
5-Year Change	N/A
10-Year Change	110.73%
Growth Volatility	75.15

Lyka Labs Limited - Net Assets Trend (2005–2025)

This chart illustrates how Lyka Labs Limited's net assets have evolved over time, based on quarterly financial data. See LYKALABS defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Lyka Labs Limited (2005–2025)

The table below shows the annual net assets of Lyka Labs Limited from 2005 to 2025. For live valuation and market cap data, see market value of Lyka Labs Limited.

Year	Net Assets	Change
2025-03-31	Rs1.04 Billion ≈ $11.20 Million	+51.73%
2024-03-31	Rs682.65 Million ≈ $7.38 Million	+49.47%
2023-03-31	Rs456.71 Million ≈ $4.94 Million	+238.53%
2022-03-31	Rs134.91 Million ≈ $1.46 Million	+153.76%
2021-03-31	Rs-250.93 Million ≈ $-2.71 Million	-66.05%
2020-03-31	Rs-151.11 Million ≈ $-1.63 Million	-133.02%
2019-03-31	Rs457.59 Million ≈ $4.95 Million	-21.43%
2018-03-31	Rs582.36 Million ≈ $6.30 Million	+38.32%
2017-03-31	Rs421.01 Million ≈ $4.55 Million	-14.35%
2016-03-31	Rs491.54 Million ≈ $5.32 Million	+5.55%
2015-03-31	Rs465.71 Million ≈ $5.04 Million	-16.86%
2014-03-31	Rs560.17 Million ≈ $6.06 Million	-19.70%
2013-03-31	Rs697.62 Million ≈ $7.54 Million	-7.69%
2012-03-31	Rs755.73 Million ≈ $8.17 Million	-46.98%
2010-03-31	Rs1.43 Billion ≈ $15.41 Million	+14.61%
2009-03-31	Rs1.24 Billion ≈ $13.45 Million	+59.29%
2008-03-31	Rs780.73 Million ≈ $8.44 Million	+69.45%
2007-03-31	Rs460.74 Million ≈ $4.98 Million	+60.96%
2005-03-31	Rs286.25 Million ≈ $3.10 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Lyka Labs Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 130135200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Common Stock	Rs356.90 Million	34.47%
Other Comprehensive Income	Rs99.06 Million	9.57%
Other Components	Rs1.88 Billion	181.64%
Total Equity	Rs1.04 Billion	100.00%

Lyka Labs Limited Competitors by Market Cap

The table below lists competitors of Lyka Labs Limited ranked by their market capitalization.

Company	Market Cap
Hulamin JSE:HLM	$27.05 Million
East Asia Holdings Investment Limited KQ:900110	$27.05 Million
Triniti Dinamik PT Tbk JK:TRUE	$27.06 Million
Advance NanoTek Limited F:BBJ	$27.06 Million
Comms Group Ltd AU:CCG	$27.04 Million
Barinthus Biotherapeutics plc NASDAQ:BRNS	$27.03 Million
KCP Sugar and Industries Corporation Limited NSE:KCPSUGIND	$27.03 Million
Utron Ltd TA:UTRN	$27.02 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Lyka Labs Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 681,543,000 to 1,035,502,000, a change of 353,959,000 (51.9%).
Net income of 80,120,000 contributed positively to equity growth.
Share repurchases of 272,025,000 reduced equity.
New share issuances of 272,025,000 increased equity.
Other comprehensive income decreased equity by 88,861,000.
Other factors increased equity by 362,700,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Rs80.12 Million	+7.74%
Share Repurchases	Rs272.02 Million	-26.27%
Share Issuances	Rs272.02 Million	+26.27%
Other Comprehensive Income	Rs-88.86 Million	-8.58%
Other Changes	Rs362.70 Million	+35.03%
Total Change	Rs-	51.93%

Book Value vs Market Value Analysis

This analysis compares Lyka Labs Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.44x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has increased from 2.25x to 2.44x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2005-03-31	Rs31.13	Rs70.06	x
2007-03-31	Rs33.04	Rs70.06	x
2008-03-31	Rs45.89	Rs70.06	x
2009-03-31	Rs71.92	Rs70.06	x
2010-03-31	Rs64.97	Rs70.06	x
2012-03-31	Rs34.23	Rs70.06	x
2013-03-31	Rs31.02	Rs70.06	x
2014-03-31	Rs24.43	Rs70.06	x
2015-03-31	Rs19.95	Rs70.06	x
2016-03-31	Rs-12.97	Rs70.06	x
2017-03-31	Rs17.79	Rs70.06	x
2018-03-31	Rs20.51	Rs70.06	x
2019-03-31	Rs15.73	Rs70.06	x
2020-03-31	Rs-5.03	Rs70.06	x
2021-03-31	Rs-8.99	Rs70.06	x
2022-03-31	Rs4.65	Rs70.06	x
2023-03-31	Rs15.79	Rs70.06	x
2024-03-31	Rs20.67	Rs70.06	x
2025-03-31	Rs28.69	Rs70.06	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Lyka Labs Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 7.74%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 5.69%
• Asset Turnover: 0.80x
• Equity Multiplier: 1.70x
Recent ROE (7.74%) is below the historical average (8.39%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2005	-1.76%	-1.10%	0.33x	4.90x	Rs-33.65 Million
2007	-24.52%	-14.52%	0.49x	3.47x	Rs-159.06 Million
2008	5.37%	4.67%	0.49x	2.36x	Rs-36.18 Million
2009	-3.97%	-2.97%	0.54x	2.48x	Rs-170.98 Million
2010	1.72%	1.73%	0.39x	2.54x	Rs-116.10 Million
2012	-0.66%	-0.45%	0.38x	3.82x	Rs-78.73 Million
2013	-1.06%	-0.56%	0.44x	4.32x	Rs-74.03 Million
2014	-12.50%	-5.54%	0.36x	6.25x	Rs-118.61 Million
2015	-11.49%	-2.98%	0.60x	6.47x	Rs-92.55 Million
2016	0.00%	2.89%	0.53x	0.00x	Rs65.85 Million
2017	-14.13%	-5.57%	0.40x	6.34x	Rs-94.59 Million
2018	-32.60%	-30.65%	0.24x	4.44x	Rs-225.75 Million
2019	-12.39%	-8.64%	0.30x	4.85x	Rs-100.32 Million
2020	0.00%	-109.27%	0.28x	0.00x	Rs-591.07 Million
2021	0.00%	-17.22%	0.35x	0.00x	Rs-89.75 Million
2022	292.39%	21.24%	0.99x	13.92x	Rs376.66 Million
2023	-29.08%	-14.41%	0.61x	3.33x	Rs-177.56 Million
2024	-3.65%	-2.37%	0.67x	2.30x	Rs-93.05 Million
2025	7.74%	5.69%	0.80x	1.70x	Rs-23.43 Million

Industry Comparison

This section compares Lyka Labs Limited's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $5,702,468,000
Average return on equity (ROE) among peers: 11.30%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Lyka Labs Limited (LYKALABS)	Rs1.01 Billion	-1.76%	0.66x	$27.04 Million
Blue Jet Healthcare Limited (BLUEJET)	$3.40 Billion	40.73%	0.58x	$958.43 Million
Concord Biotech Limited (CONCORDBIO)	$12.90 Billion	18.61%	0.17x	$1.52 Billion
Dishman Carbogen Amcis Limited (DCAL)	$12.02 Billion	9.09%	1.15x	$288.43 Million
SMS Lifesciences India Limited (SMSLIFE)	$1.06 Billion	16.78%	1.54x	$42.13 Million
Supriya Lifescience Limited (SUPRIYA)	$8.15 Billion	14.61%	0.13x	$811.42 Million
Take Solutions Limited (TAKE)	$109.18 Million	4.10%	0.30x	$47.06 Million
Zota Health Care LImited (ZOTA)	$2.27 Billion	-24.83%	0.93x	$418.05 Million

About Lyka Labs Limited

NSE:LYKALABS India Biotechnology

Market Cap

$27.04 Million

Rs2.50 Billion INR

Market Cap Rank

#24155 Global

#1331 in India

Share Price

Rs70.06

Change (1 day)

-0.64%

52-Week Range

Rs44.95 - Rs116.18

All Time High

Rs254.30